600200，重大违法强制退市！停牌前还五连涨停

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (ST Wuzhong) has been penalized by the China Securities Regulatory Commission (CSRC) for failing to disclose its actual controller and for false records in its annual reports from 2018 to 2023, leading to a warning, a fine of 10 million yuan, and a forced delisting of its stock starting November 26, 2025 [1][4]. Group 1 - The company failed to disclose its actual controller, with the reports from 2018 to 2023 falsely identifying Qian Qunying as the actual controller instead of Qian Qunshan, who became the actual controller after a shareholding change in February 2018 [1][2]. - There were inflated operating revenues, costs, and profits in the annual reports from 2020 to 2023, with subsidiaries engaging in non-substantive trade activities to artificially boost financial figures [2]. - The company did not disclose the non-operating fund occupation by related parties in its reports from 2020 to 2023, which constituted significant omissions [3]. Group 2 - The CSRC imposed a fine of 10 million yuan on ST Wuzhong and issued warnings to responsible individuals, with Qian Qunshan facing a total fine of 15 million yuan and a 10-year ban from the securities market [4]. - Other penalties included fines for the vice chairman, board members, and the financial director, totaling 2.05 million yuan for various individuals involved [4]. - Prior to the announcement of the suspension, ST Wuzhong had achieved a "five consecutive boards" increase, with its stock price at 1.24 yuan, reflecting a 5.08% increase and a market capitalization of approximately 880 million yuan [6].